• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

UCLA Scientists Advance Cancer-screening Technology to Personalize Treatment

  UCLA Scientists Advance Cancer-screening Technology to Personlize Treatment  
 

Parallel microfluidic vortex chambers accumulate
larger circulating tumor cells from flowing blood.
Image: Courtesy of Dr. Dino Di Carlo

Despite a growing interest in developing noninvasive methods to identify rare cancer cells or cancer-cell DNA in blood, current techniques remain complicated and often prohibitively expensive. Now, UCLA researchers have pioneered a more effective approach to these “liquid biopsies” that has the potential to offer a streamlined and low-cost solution for people with the disease.

The technology works by creating millimeter-scale whirlpools to draw in and concentrate circulating tumor cells, known as CTCs, based on their size. CTCs often appear as large abnormal cells in the circulation of cancer patients and can be used by scientists as cellular markers of the disease. Analysis of these cells promises to provide critical information about which treatments are best suited and most effective for a patient and whether or not those receiving a therapy may relapse.

“CTCs are extremely rare, so isolating them is a problem similar to finding a needle in a haystack,” says Dino Di Carlo, PhD, director of UCLA’s Jonsson Comprehensive Cancer Center Nanotechnology Program and professor of bioengineering at UCLA’s Henry Samueli School of Engineering and Applied Science. “Our filterless system avoids issues of previous technologies that clog and break cells apart, and we found this approach was more effective than technologies currently available at isolating cells from breast- and lung-cancer patients.”

In a two-year study, Dr. Di Carlo’s team isolated cells and detected specific proteins on these cells from 50 patients. In a subset of these patients, they compared the number of CTCs discovered by the U.S. Food and Drug Administration-approved gold-standard instrument. What they found was a significantly higher number of cells per patient, with more than 80 percent of patients having CTC levels above age-matched healthy individuals, compared to only 20 percent with the currently approved instrument.

In a previous study published in 2014, the researchers discovered that the micro-whirlpools, or vortices, entrapped cancer cells with epithelial characteristics in a small number of patients (epithelial cells help to protect or enclose organs within the body). The new findings showed that nearly half of the CTCs isolated with this new Vortex HT system developed by UCLA researchers didn’t have epithelial-like markers and that the number of CTCs isolated was almost doubled compared to the previous iteration of the technology.

Dr. Di Carlo said he hopes the new system will enable clinicians to better understand how to administer and monitor treatments. In the long term, he hopes an approach could potentially be used to detect cancer earlier with a simple blood test.

“Classification of Large Circulating Tumor Cells Isolated with Ultra-high Throughput Microfluidic Vortex Technology,” Oncotarget, February 6, 2016


Previous
UCLA Researchers Grow 3D Lung-in-a-dish
Next
Heart-failure Therapy Could Reduce Deaths


YOU ARE VIEWING

Fall 2016

Fall 2016
E-Brochure
Printable PDF
IN THIS ISSUE
  • Brave New World
  • A Humble Leader
  • Impaired Decision-making May Contribute to Parkinson’s Motor Symptoms
  • Biomarkers Could Give Cancer Patients Better Survival Estimates
  • UCLA Researchers Grow 3D Lung-in-a-dish
  • UCLA Scientists Advance Cancer-screening Technology to Personalize Treatment
  • Heart-failure Therapy Could Reduce Deaths
  • Fructose Alters Brain Genes, Can Lead to Disease
  • New Method to Study Mitochondrial DNA Diseases
  • Potential Treatment Breakthrough for Advanced Brain Cancer
  • UCLA, Danish Researchers Explain How Eliminating HIV Is Possible
  • Eye on the Future
  • The Collaborator
  • Lonely Planet
  • Bridging the Cultural Divide
  • Heart to Heart
  • Awards & Honors
  • In Memoriam
  • The Long Road from California to the CDC
  • Like Father, Like Son
  • Generous Philanthropic Gift Will Name the UCLA Division of Digestive Diseases
  • Cancer Moonshot Summit Aspires to Eclipse Cancer
  • Kaleidoscopic Circus Celebration Raises Money for Children’s Research
  • Who Cares About the Next Generation
  • Cancer Crusader Establishes Women’s Cancer-research Fund
  • Longtime UCLA Benefactor Expands Commitment to Alzheimer’s Care
  • Symposium on Teen Self-image
  • Medical School Alumni Reunite and Tour Geffen Hall
  • Heart Talk: Women’s Heart Health Program Reaches Out to the Community
  • UCLA Medical Center Boards Welcome New Leadership
  • Gifts
  • ACT III
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth